Dr. Cantley is a co-founder of Volastra and a world-renowned biologist and biochemist. He is celebrated, in particular, for his discovery of the phosphoinositide 3-kinase (PI3K) signaling pathway in the 1980s. Dr. Cantley’s lab at Dana Farber Cancer Institute investigates cancer metabolism and phosphoinositide signaling and his former lab at Weill Cornell Medical College was the first lab to identify the link between chromosomal instability and cytosolic DNA signaling in cancer metastases. Dr. Cantley is a member of the National Academy of Sciences and National Academy of Medicine and has received a number of awards for his research, most recently the 2019 Horwitz Prize. He has founded several companies, including Volastra Therapeutics.